What are the potential thymosin alpha-1 benefits?

The best-supported potential benefit is immune modulation in specific disease settings, not a universal boost to immunity. Laboratory work shows effects on dendritic-cell signaling and T-cell maturation. Human trials have explored chronic hepatitis, sepsis, cancer adjunct care and COVID-19, but their results are mixed and the strongest sepsis and hepatitis C trials did not show a significant primary benefit.

Does thymosin alpha-1 boost the immune system?

It is more accurate to call thymosin alpha-1 an immune modulator. Cell and animal studies show that its effects depend on the immune signal and context, including Toll-like receptor pathways and dendritic cells. That is different from showing fewer everyday infections or better general wellness in healthy people, outcomes that have not been established in large randomized trials.

What did thymosin alpha-1 sepsis trials find?

The findings changed with trial size. ETASS reported 28-day mortality of 26.0% versus 35.0%, but its primary nonstratified analysis missed statistical significance at P=0.062. The later TESTS phase 3 trial enrolled 1,106 adults and found 28-day mortality of 23.4% versus 24.1%, with no statistically significant difference in secondary or safety outcomes.

Has thymosin alpha-1 shown benefits in hepatitis or cancer?

Some smaller studies reported favorable numerical or virological signals, but confirmatory findings were weak. A phase 3 hepatitis B trial reported 14% complete response versus 4% with placebo, P=0.084, and a 552-person hepatitis C trial found 12.7% versus 10.5%, P=0.407. Cancer trials studied thymalfasin only as an adjunct and did not establish a stand-alone cancer benefit.

What do the COVID-19 studies show?

The observational data conflict. One 76-case retrospective study associated thymosin alpha-1 with lower mortality, while a five-hospital cohort of 2,282 patients associated its use with higher adjusted non-recovery. Because treatment was not randomized and sicker patients may have been more likely to receive it, neither result can establish that thymosin alpha-1 caused benefit or harm.

Is thymosin alpha-1 approved in the United States?

No. Thymalfasin is marketed as Zadaxin and has approvals in more than 35 countries, but it has not received FDA approval in the United States. Promise's compounded formulation is different from an FDA-approved product and is not FDA-approved. A licensed provider may still prescribe a compounded formulation when medically appropriate after reviewing the patient's history.

Thymosin Alpha-1 Benefits: What Studies Show

Thymosin alpha-1 benefits are best understood as research signals in specific diseases, not as proof of broad “immune boosting.” Laboratory studies show effects on dendritic-cell signaling and T-cell development. In people, some hepatitis, sepsis, cancer and COVID-19 studies reported favorable outcomes, while larger or better-controlled trials often did not reach statistical significance. The honest conclusion is that thymalfasin has a credible immune-modulating mechanism and a substantial clinical literature, but no established benefit for general wellness.

For the molecule itself, start with the thymosin alpha-1 overview. Its dosing evidence is covered separately; the trial schedules below are not a personal treatment plan.

How thymosin alpha-1 benefits could arise

Thymosin alpha-1 appears to modulate immune responses rather than simply turn them up. In a 2004 laboratory and mouse study, it promoted dendritic-cell maturation and interleukin-12 production through MyD88-dependent Toll-like receptor signaling, then increased antifungal T-helper-1 activity (Romani et al., Blood 2004). That is a plausible bridge between early pathogen sensing and a more targeted adaptive response, but it is not a clinical outcome in humans.

The T-cell maturation claim also starts in the laboratory. In a human thymic-cell coculture model, thymosin alpha-1 increased mature CD3+CD4+ cells derived from CD34+ stem cells (Knutsen et al., International Journal of Immunopharmacology 1999). These findings explain why researchers tested thymalfasin when illness was associated with immune suppression. They do not show that it prevents routine infections in otherwise healthy adults.

Research area	Strongest signal	Main limit
Immune signaling	TLR-linked dendritic-cell activity and T-cell maturation	Mostly cell and animal models
Chronic hepatitis	Some smaller HBV trials reported delayed viral responses	Confirmatory HBV and large HCV trials missed primary endpoints
Sepsis	ETASS reported a numerical mortality difference	The larger TESTS trial found no mortality difference
Cancer adjunct	Numerical signals when added to cancer therapy	No stand-alone benefit established
COVID-19	Early retrospective cohorts pointed in opposite directions	Treatment was not randomized

Hepatitis B and C results were mixed

The hepatitis B record contains the clearest positive signal and an equally important failure to confirm it. A 98-person randomized trial reported complete virological response at 18 months in 40.6% of the 26-week group, 26.5% of the 52-week group and 9.4% of untreated controls; only the 26-week comparison reached significance (Chien et al., Hepatology 1998). The delayed response after treatment was one reason the molecule stayed in development.

A later phase 3, double-blind hepatitis B trial was less convincing. Complete response occurred in 14% of 49 thymalfasin recipients and 4% of 48 placebo recipients, but the difference did not reach statistical significance at P=0.084 (Mutchnick et al., Journal of Viral Hepatitis 1999).

Hepatitis C produced a larger null result. In 552 prior nonresponders, adding thymosin alpha-1 to peginterferon and ribavirin yielded sustained virological response in 12.7% versus 10.5% with placebo, P=0.407 (Ciancio et al., Journal of Viral Hepatitis 2012). These disease-specific results cannot be converted into a general claim of antiviral protection.

Sepsis: an early signal did not hold up

ETASS randomized 361 adults with severe sepsis. Twenty-eight-day mortality was 26.0% with thymosin alpha-1 and 35.0% with control care, but the prespecified nonstratified analysis did not reach significance: relative risk 0.74, 95% confidence interval 0.54–1.02, P=0.062. The study did report larger increases in monocyte HLA-DR, an immune-function marker, on days 3 and 7 (Wu et al., Critical Care 2013).

The larger TESTS phase 3 trial is the more decisive result. It enrolled 1,106 adults at 22 Chinese centers; in the modified intention-to-treat analysis, 28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo. No secondary or safety outcome differed significantly (Wu et al., BMJ 2025).

A related 2022 Chinese multicenter trial tested the immune-enhancement premise in acute necrotizing pancreatitis, not sepsis. Among 508 participants, infected pancreatic necrosis occurred in 15.7% with thymosin alpha-1 and 18.1% with placebo, a nonsignificant difference of −2.4 percentage points, P=0.48 (Ke et al., Intensive Care Medicine 2022). Together, these trials make a broad critical-illness benefit hard to defend.

Oncology studies tested an adjunct, not a cancer treatment

Cancer studies added thymalfasin to established therapy; they did not test it as a replacement. In a 488-person metastatic melanoma study, median overall survival across the thymosin alpha-1 arms was 9.4 months versus 6.6 months in the control arm. The hazard ratio was 0.80 and the P value was 0.08, so the survival difference was not statistically significant (Maio et al., Journal of Clinical Oncology 2010).

A 25-person liver-cancer pilot likewise found numerical differences when thymalfasin was added to transarterial chemoembolization, but neither response nor median overall survival differed significantly (Gish et al., Hepatology International 2009). These are reasons for further study, not evidence that thymosin alpha-1 treats cancer.

COVID-19 observations point both ways

Early COVID-19 evidence shows why observational findings need restraint. A retrospective study of 76 severe cases reported mortality of 11.11% with thymosin alpha-1 versus 30.00% without it, P=0.044, alongside changes in T-cell counts and exhaustion markers (Liu et al., Clinical Infectious Diseases 2020).

A much larger five-hospital cohort reached the opposite association. Among 2,282 patients, the 306 who received thymosin alpha-1 were sicker on crude measures; after adjustment, treatment was still associated with higher non-recovery, odds ratio 1.5, 95% confidence interval 1.1–2.1 (Liu et al., Frontiers in Immunology 2021). Confounding by illness severity can distort either direction. Neither cohort proves benefit or harm, and neither establishes routine immune support.

What this evidence can guide

Thymalfasin, marketed as Zadaxin, is approved in more than 35 countries according to a peer-reviewed regulatory review (Goldstein and Goldstein, Expert Opinion on Biological Therapy 2009), but it is not FDA-approved in the United States; the FDA orphan-drug record lists it as designated but not approved for chronic hepatitis B (FDA orphan-drug database).

Promise's thymosin alpha-1 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality before they are marketed (FDA compounding questions and answers). A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor.

At Promise, a licensed U.S. provider reviews every request and not everyone qualifies. A useful review asks whether the intended goal resembles a studied population, how immune-active conditions or medicines change the risk, and what outcome would justify continuing. The separate guide to thymosin alpha-1 side effects covers tolerability and uncertainty, while the immune-support hub puts the option in context.